PKU: Pre-Clinical Kinetic Data Showing Prolonged Release of Amino Acids Thanks to the Innovative Physiomimic Technology by APR Presented at the 13th ICIEM Congress (September 5th-8th, Rio de Janeiro)
APR Applied Pharma Research s.a. (“APR”), the Swiss independent developer of science driven and patent protected healthcare products, announces today the results of a pre-clinical kinetic study showing a physiological absorption of clinically relevant groups of amino acids (AAs) thanks to the application of the patented Physiomimic™ drug delivery Technology platform. APR’s innovative product is intended to be used for the management of patients with phenylketonuria (PKU).
The results of the investigation indicate that the Physiomimic™ Technology by APR is able to modify the release of clinically relevant AAs by lowering and retarding their absorption profiles if compared to the same mix of amino acids without the application of the technology. Also remarkable is that the kinetic profile of the AAs engineered with the Physiomimic™ Technology resembles that of casein - a reference food protein known to have a prolonged absorption profile.
The study suggests that APR’s advanced formulation of AAs has the
potential of contributing to maintain Phenylalanine (“PHE”) levels
within the recommended ranges, with less prominent fluctuations of
PHE levels over time, thanks to a prolonged release of the AAs in the
gut, which is thought to allow a more efficient utilization of the
absorbed amino acids, PHE included.
Furthermore, the Physiomimic™ Technology has the ability of remarkably masking their taste and odor, with potential positive consequences on aftertaste for an exceptionally palatable product.
The outcome of the pre-clinical study will be presented in an oral presentation (Gut Microbiota and Human Metabolism” Thursday September 7 th 2017, 11.00-12.30) during the 13th International Congress of Inborn Errors of Metabolism in Rio de Janeiro on September 5 - 8, 2017 (ICIEM 2017). A poster will also illustrate the results of the application of the innovative Physiomimic™ Technology (Attended Poster Session Wednesday September 6 th 17:30 – 20:00) to amino acids for PKU.
“For the first time, the application of a pharmaceutical drug delivery technology platform to a Medical Food leads to a real change in PKU management.” Paolo Galfetti, CEO of Applied Pharma Research, states. “Since data show that there are still open issues in the management of PKU, we developed the Physiomimic™ Technology with the aim of meaningfully contributing to fulfill significant unmet needs of this disorder, providing patients, Healthcare Professionals (HCPs) and care givers with a product that would deliver amino acids in a physiological manner, whilst being very palatable and thus significantly improving patient compliance”.
“The development plan to characterize our innovative product for PKU is robust, - adds Giorgio Reiner, Corporate Director R&D of Applied Pharma Research – “with the next major step being a clinical kinetic study in human volunteers as a proof of concept of the prolonged release of Amino Acids and their consequent physiological absorption. Other pre-clinical studies as well as clinical evidences will reinforce the scientific profile of our proprietary technology and product to help us continue this journey.”
On October 5th-8th, APR will also sponsor the 31 st E.S. PKU Conference (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria), in Hell, Norway continuing to contribute to the advancement of the management of this rare disorder.
About APR Applied Pharma Research s.a.
APR is a Swiss, independent developer of science driven, patent protected Healthcare products. The Company identifies, develops and licenses science driven, value added products designed to address patient or consumer needs in selected therapeutic areas on a global basis. In particular, APR is currently focused on 2 (two) areas: (i) internally developed and financed (alone or together with our co-development partners) proprietary, value added products to be licensed to healthcare companies for their commercialization, and (ii) support to third party projects by offering added value R&D services under contract and fee for service arrangements. APR has a balanced pipeline of revenue generating branded products marketed in all major markets combined with a compelling pipeline of products at different stage of development. APR has entered into licensing and partnership agreements with pharmaceutical companies, in over 70 countries with international sales on a worldwide basis.
About Phenylketonuria or PKU
Phenylketonuria or PKU is a rare, genetic, recessive metabolic disorder affecting about 50.000 people worldwide. PKU is characterized by the deficiency or the malfunctioning of a liver enzyme needed to process phenylalanine (“PHE”), an essential amino acid found in most protein-containing food. Excessive amounts of PHE in the bloodstream become toxic to the brain, impairing the normal development of the central nervous system. If not properly treated, PKU leads to severe, non-recoverable mental retardation and major cognitive disabilities. PKU can only be treated through a strict, life-long, low-protein (low-PHE) dietetic treatment combined with a daily assumption of low-protein modified foods and Medical Food which provides PHE-free amino acids and other important nutrients, needed due to the dietary restrictions of PKU patients.
For more information about Physiomimic™ Technology, please visit: www.apr.ch/apr-pharma-products/medical-prescription/genetic-metabolic-disease/
For press releases and other company information visit: www.apr.ch
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
IBC2017 Reports Record Visitor Numbers in Its 50th Year22.9.2017 09:32 | Pressemelding
In its 50th anniversary, IBC2017 has confirmed a year-on-year increase in visitor numbers, marking a record attendance of 57,669 across the six day event. Visitors from across the expanding media ecosystem had the opportunity to learn about the opportunities offered by technologies - including social media TV, OTT, VR, AR, Cloud, IP, Bots and 5G - and to meet the most intelligent robots. Visitors to the 15 exhibition halls witnessed many exciting new launches; Launch Pad grew year-on-year with a record number of exhibitors; the Future Reality Theatre and Content Everywhere Hub free programmes were packed with diverse and new exciting content, embracing the transformation. Conference delegates packed the Forum to hear from leading experts from Facebook, Google, CNN, HTC Viveport, Dolby, C4 and ITV to discuss and debate the hot topics challenging the industry with a focus on m
The Listing of Money Trade Coin on Cryptocurrency Exchange and the Rising Promise of a New Era in Dubai21.9.2017 17:45 | Pressemelding
MONEY TRADE COIN, the new age cryptocurrency, dazzled its investors’ expectations by listing on NovaExchange. Immediate trading began post the launch by Money Trade Coin’s founder and CEO, Mr. Amit Lakhanpal and H.E. Sheikh Saqer Al Nahyan. The listing event held on September 17 at Burj Al Arab was witnessed by a list of 40 VIP businessmen including H.E. Sheikh Jumaa Al Maktoum, Mr. Faisal Almaazmi, his principal advisor and director of Greenland Capital Properties, Mr. Charles Said Kiwan founder of MVP Tech and Mr. Khaled Abdulla, Head of Communications MENA at Barclays PLC. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921006013/en/ Amit Lakhanpal greets H.E. Sheikh Saqer Al Nahyan (Photo: AETOS Wire) Money Trade Coin, the propagator of the “Cryptocurrency correct knowledge” l
Triaconta Announces a New Safe Way to Invest in Cryptocurrencies21.9.2017 16:18 | Pressemelding
Triaconta wants to minimize the risks of investing in cryptocurrencies with Combicoin to make the cryptocurrency market accessible for a larger audience. CombiCoin is 100% asset backed by the top 30 cryptocurrencies with the highest market cap. Because of this the CombiCoin will not suddenly plunge and investors will have less risks when there are major fluctuations. There are over 1000 cryptocurrencies on the market and together they represent a value of 130 billion USD. However, all these coins are very volatile. For example, the value of bitcoin grew from 1000 to 4000 USD within six months. The value of Ethereum, the second largest cryptocurrency, rose from 150 to 400 USD within 6 months but plunged to 150 USD 4 weeks later. In the first six months of 2017 the top 30 of cryptocurrencies grew with 1200 percent. The value of CombiCoin is determined for 3.3
TIP Trailer Services Announces the Successful Refinancing of its ABS program21.9.2017 15:16 | Pressemelding
On 21 September 2017, TIP Trailer Services announced that it had successfully refinanced its Asset Backed Securitisation (ABS) program. The Pan-European program was originally established in 2014 and is a securitisation structure common under Dutch law for operating leases. The new program will run until March 2019. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005815/en/ At the official signing of the TIP ABS refinancing were: From left to right: Jorrit Achterberg (Legal Counsel, TIP Trailer Services), Patrick Vergouwen (International Investor Relations Manager, TIP Trailer Services), Bart de Boo (Director, Asset Based Finance, Rabobank), Gert Huizing (Quality Assurance Manager Capital Market Services, Intertrust), Leo van der Sman (Legal Counsel, Intertrust) (Photo: Business Wire) “The extra funding and improved co
Tohatsu, Major Outboard Manufacturer, to Launch Global Brand Campaign Targeting Millennial Generation Boat Users21.9.2017 14:30 | Pressemelding
On September 21, 2017, Tohatsu Corporation (headquartered in Tokyo, Japan; hereinafter "TOHATSU") announced the outline of its global brand campaign at the 57th Genoa International Boat Show held in Genova, Italy. TOHATSU’s global brand campaign based on a new branding strategy will be deployed at boat shows around the world, starting from the Genoa International Boat Show in September 2017. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170921005018/en/ Feel the Wind (Photo: Business Wire) The campaign sets “SMARTS” millennials as its core target, revealing TOHATSU’s new brand logo, “Blue Wings” and its unique “Simpliq™ Technology” The feature of the new branding strategy is its target demographic called “SMARTS”, millennial boat owners (born between 1977 and 199
Sigma Systems Chief Technology Officer to Address CSPs at Futurecom 201721.9.2017 14:00 | Pressemelding
Sigma Systems, the global leader in catalog-driven software, has today announced that its Chief Technology Officer, Catherine Michel, will be speaking at Futurecom 2017 – the largest ICT event in Latin America. Catherine will address communications service providers (CSPs) and industry professionals at the Sao Paulo event on what’s driving the digitalization mandate for operators. Ahead of her presentation, Catherine commented: “The digitalization of the CSP is about transforming business operations, based on a thorough understanding of customer needs, behaviours and experiences. This requires a shift in corporate culture, and many CSPs are not making the changes necessary to embrace digital innovation and become market leading digital service providers. To deliver on a digital transformation, operators must embrace digital innovation and enable the rapid launch a
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom